^
No biomarker
Germ Cell Tumors
dactinomycin
Sensitive: A1 - Approval
No biomarker
Germ Cell Tumors
ifosfamide
Sensitive: A1 - Approval
No biomarker
Germ Cell Tumors
TI-CE
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
CaT
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
VC
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
GemOx
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
BEP
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
EP
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
VIP
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
VAC
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
VeIP
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
TIP
Sensitive: A2 - Guideline
TMB-H
Germ Cell Tumors
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
carboplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
docetaxel
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Germ Cell Tumors
paclitaxel + gemcitabine + oxaliplatin
Sensitive: A2 - Guideline
MSI-H/dMMR
Germ Cell Tumors
pembrolizumab
Sensitive: A2 - Guideline
BRCA1 mutation
Germ Cell Tumors
olaparib
Sensitive: C1 - Off-label
XPA expression
Germ Cell Tumors
cisplatin
Resistant: C3 – Early Trials
MTOR mutation
Germ Cell Tumors
everolimus
Sensitive: C3 – Early Trials
KRAS amplification
Germ Cell Tumors
MEK inhibitor
Sensitive: C3 – Early Trials
Chr t(22)
Germ Cell Tumors
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive: C4 – Case Studies
EGFR L858R
Germ Cell Tumors
icotinib
Sensitive: C4 – Case Studies
BAX underexpression
Germ Cell Tumors
cisplatin
Resistant: C4 – Case Studies
TP53 mutation
Germ Cell Tumors
cisplatin
Resistant: C4 – Case Studies
EGFR L858R
Germ Cell Tumors
icotinib
Sensitive: C4 – Case Studies
PLAC8 overexpression
Germ Cell Tumors
etoposide oral
Resistant: D – Preclinical
BRCA1 expression
Germ Cell Tumors
olaparib
Resistant: D – Preclinical
RAD51C expression
Germ Cell Tumors
olaparib
Resistant: D – Preclinical